Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
European Pharmaceutical Journal
Volume 69 (2022): Issue s1 (July 2022)
Open Access
Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience
Jan Juřica
Jan Juřica
,
Roman Goněc
Roman Goněc
,
Adela Bártová
Adela Bártová
and
Jana Gregorová
Jana Gregorová
| Jun 18, 2022
European Pharmaceutical Journal
Volume 69 (2022): Issue s1 (July 2022)
About this article
Previous Article
Next Article
Abstract
Article
Figures & Tables
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Article Category:
Short Communication
Published Online:
Jun 18, 2022
Page range:
84 - 86
Received:
Apr 25, 2022
Accepted:
May 10, 2022
DOI:
https://doi.org/10.2478/afpuc-2022-0006
Keywords
Immune checkpoint inhibitors
,
immunotherapy
,
adverse effect
,
autoimmunity
© 2022 Jan Juřica et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.